Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)

Conditions:   Gastric Neoplasms;   Gastroesophageal Junction Adenocarcinoma
Interventions:   Biological: Pembrolizumab;   Drug: Paclitaxel
Sponsor:   Merck Sharp & Dohme Corp.
Not yet recruiting - verified January 2017

http://ift.tt/2jbsSXs